Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases driven by excess insulin. Its lead candidate, ersodetug, is a monoclonal antibody in Phase 3 programs for hypoglycemia due to congenital hyperinsulinism and tumor hyperinsulinism. The focus is ultra-rare conditions where uncontrolled insulin release causes dangerous low blood sugar and limited standard options exist.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -18.9 | — |
| Q2 2025 | 0 | — | -24.4 | — |
| Q3 2025 | 0 | — | -18.1 | — |
| Q4 2025 | 0 | — | -22.8 | — |
| Q1 2026 | 0 | — | -16.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Ocugen, Inc. (OCGN), American Coastal Insurance Corporation (ACIC), BTQ Technologies Corp. (BTQ), Prelude Therapeutics Incorporated (PRLD), Infinite Eagle Acquisition Corp. (IEAG), Carlsmed, Inc. (CARL)